Recurrent Childhood Soft Tissue Sarcoma Completed Phase 1 Trials for Tanespimycin (DB05134)

IndicationStatusPhase
DBCOND0029296 (Recurrent Childhood Soft Tissue Sarcoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00093821Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsTreatment